POINT Biopharma Global Q2 EPS $(0.15) Down From $(0.07) YoY

POINT Biopharma Global (NASDAQ:PNT) reported quarterly losses of $(0.15) per share. This is a 114.29 percent decrease over losses of $(0.07) per share from the same period last year.

byBill Haddad

August 13, 2021

1 minute read

POINT Biopharma Global (NASDAQ:PNT) reported quarterly losses of $(0.15) per share. This is a 114.29 percent decrease over losses of $(0.07) per share from the same period last year.

Is Now The Time To Buy Into GameStop, Orbsat, Or Amazon?

By Shivdeep Dhaliwal

Today, 4:18 PM

The following three stocks are on the radar of retail investors and day traders early Wednesday.

AMC

Groupon Q4 EPS $0.18 Misses $0.19 Estimate, Sales $223.16M Miss $223.53M Estimate

By Benzinga Newsdesk

Today, 4:18 PM

Groupon (NASDAQ:GRPN) reported quarterly earnings of $0.18 per share which missed the analyst consensus estimate of $0.19 by 5.26 percent. This is a 64.71 percent decrease over earnings of $0.51 per share from the same

GRPN

Wall Street’s Most Accurate Analysts Reshuffled Their Best Chinese Internet Picks, Here They Are

By Lisa Levin

Today, 4:18 PM

Investors are carefully monitoring Chinese tech stocks amid protests over COVID-19 restrictions. China's central bank last week loosened bank reserve requirements.

BABA

Zymeworks To Cut Its Workforce By Almost 25%, Outlines 2022 & 2023 Priorities

By Vandana Singh

Today, 4:18 PM

Zymeworks Inc (NYSE: ZYME) said that in conjunction with the renewed focus on key priorities and cost-efficiency, ten members (or 50%) of the former senior management team would be leaving the Company.

ZYME

POINT Biopharma Global Q2 EPS $(0.15) Down From $(0.07) YoY

Related Posts

Is Now The Time To Buy Into GameStop, Orbsat, Or Amazon?

Groupon Q4 EPS $0.18 Misses $0.19 Estimate, Sales $223.16M Miss $223.53M Estimate

Wall Street’s Most Accurate Analysts Reshuffled Their Best Chinese Internet Picks, Here They Are

Zymeworks To Cut Its Workforce By Almost 25%, Outlines 2022 & 2023 Priorities